Tozaride (Rhenium (Re) 188 P2045) / Andarix - LARVOL DELTA

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). (PubMed, Cell Rep Med) - "Here, we report interim results of a Simon's two-stage design, phase 2 trial using neoadjuvant sintilimab with carboplatin and nab-paclitaxel in resectable EGFR-mutant NSCLC. Informed circulating tumor DNA (ctDNA) detection in EGFR-mutant NSCLC could help identify patients nonresponsive to neoadjuvant immunochemotherapy. These findings provide supportive data for the utilization of neoadjuvant immunochemotherapy and insight into immune resistance in EGFR-mutant NSCLC."

IO biomarker • Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CCR8 • CXCL13 • EGFR

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Andarix Pharmaceuticals | Unknown status ➔ Recruiting | Trial completion date: Apr 2020 ➔ Apr 2025

Enrollment open • Trial completion date • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Sydney skin cancer patients join the EPIC-Skin study as they undergo first treatments with OncoBeta's Rhenium-SCT (PRNewswire) - "OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer [NMSC])....These patients were treated on 8 April and are now part of 210 adults participating in the international study that will follow their progress over the next 24 months."

Trial status • Non-melanoma Skin Cancer • Oncology • Skin Cancer

"#AndarixPharmaceuticals Awarded Trademark for #Tozaride by the US #Patent and Trademark Office https://t.co/RrmjLxsDD8" (@1stOncology)